Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 502,334,368
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • EBIT $ 16,179 M
  • EBITDA $ 17,546 M
  • 60-Month Beta 0.43
  • Price/Sales 14.90
  • Price/Cash Flow 37.18
  • Price/Book 30.94

Options Overview Details

View History
  • Implied Volatility 45.97% ( +2.10%)
  • Historical Volatility 18.69%
  • IV Percentile 99%
  • IV Rank 88.14%
  • IV High 49.01% on 08/05/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.45
  • Today's Volume 25,354
  • Volume Avg (30-Day) 27,618
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 300,995
  • Open Int (30-Day) 298,798

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.90
  • Number of Estimates 4
  • High Estimate 0.94
  • Low Estimate 0.87
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +23.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.24 +2.31%
on 10/30/24
120.56 -8.99%
on 10/11/24
-5.40 (-4.69%)
since 10/04/24
3-Month
107.24 +2.31%
on 10/30/24
139.74 -21.48%
on 08/30/24
-17.77 (-13.94%)
since 08/02/24
52-Week
94.73 +15.82%
on 12/11/23
148.15 -25.94%
on 06/25/24
+11.55 (+11.77%)
since 11/03/23

Most Recent Stories

More News
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on an operational basis, driven by higher sales of key non-COVID products like...

NVO : 109.72 (-1.98%)
LLY : 806.14 (-1.56%)
ABBV : 200.47 (-1.51%)
PFE : 27.76 (-1.17%)
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?

Size means little in light of this company's prospects.

NVO : 109.72 (-1.98%)
LLY : 806.14 (-1.56%)
Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis,...

NVO : 109.72 (-1.98%)
LLY : 806.14 (-1.56%)
Canada Jobs on Agenda for Next Week

Monday U.S. Economic Lookahead Factory orders (Sept.) Featured Earnings Vertex Pharmaceuticals ...

APO : 139.43 (-1.11%)
PBR : 13.18 (+0.53%)
ANET : 394.88 (+0.18%)
NRG : 88.05 (+1.53%)
CEG : 225.95 (-12.46%)
NVO : 109.72 (-1.98%)
VRTX : 472.80 (+0.36%)
ALC.TO : 14.96 (+0.07%)
EMR : 109.81 (+1.24%)
RBA : 85.40 (+0.35%)
CJT.TO : 138.80 (+0.53%)
QCOM : 165.18 (-0.05%)
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus

Amgen AMGN reported third-quarter 2024 adjusted earnings of $5.58 per share, which beat the Zacks Consensus Estimate of $5.11. Earnings rose 13% year over year as higher revenues offset the impact of higher...

AZN : 71.43 (+0.01%)
NVO : 109.72 (-1.98%)
LLY : 806.14 (-1.56%)
AMGN : 316.91 (-0.72%)
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering

Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors

VKTX : 63.14 (-13.36%)
NVO : 109.72 (-1.98%)
LLY : 806.14 (-1.56%)
GS : 511.47 (-1.52%)
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years

Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.

NVO : 109.72 (-1.98%)
LLY : 806.14 (-1.56%)
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever

One key disease-prevention market is drawing closer to being within reach.

NVO : 109.72 (-1.98%)
LLY : 806.14 (-1.56%)
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.

NVO : 109.72 (-1.98%)
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive talks with U.S. private equity company CD&R to sell a controlling stake in its...

AZN : 71.43 (+0.01%)
NVO : 109.72 (-1.98%)
RHHBY : 39.4300 (+0.43%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 111.66
2nd Resistance Point 111.16
1st Resistance Point 110.44
Last Price 109.72
1st Support Level 109.22
2nd Support Level 108.72
3rd Support Level 108.00

See More

52-Week High 148.15
Fibonacci 61.8% 127.74
Fibonacci 50% 121.44
Fibonacci 38.2% 115.14
Last Price 109.72
52-Week Low 94.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar